Last reviewed · How we verify
Trifluridine/Tipracil
Trifluridine/Tipracil is an antiviral drug that works by inhibiting thymidylate synthase and dihydrofolate reductase.
Trifluridine/Tipracil is an antiviral drug that works by inhibiting thymidylate synthase and dihydrofolate reductase. Used for Adenocarcinoma of the colon.
At a glance
| Generic name | Trifluridine/Tipracil |
|---|---|
| Also known as | Lonsurf |
| Sponsor | Australasian Gastro-Intestinal Trials Group |
| Drug class | Antiviral |
| Target | Thymidylate synthase, Dihydrofolate reductase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Trifluridine is a nucleoside analog that inhibits thymidylate synthase, an enzyme involved in DNA synthesis. Tipracil is a prodrug that is converted to 5-fluorouracil, which inhibits dihydrofolate reductase, another enzyme involved in DNA synthesis. This dual inhibition leads to the inhibition of DNA synthesis and cell death in rapidly dividing cells, such as cancer cells.
Approved indications
- Adenocarcinoma of the colon
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Fatigue
- Abdominal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |